News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Quark Pharmaceuticals Inc. Announces Completion Of Phase 2 Trial Evaluating QPI-1002 For Prevention Of Delayed Graft Function In Kidney Transplant Patients


7/1/2014 9:02:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FREMONT, Calif., July 1, 2014 (GLOBE NEWSWIRE) -- Quark Pharmaceuticals, Inc. today reported completion of a randomized, placebo-controlled multicenter Phase II trial of QPI-1002 for the prophylaxis of delayed graft function (DGF) in ESRD dialysis-dependent patients undergoing deceased donor kidney transplantation. The results of the trial will be presented at the 2014 World Transplant Conference in San Francisco, as an oral presentation in the late-breaking session on Monday, July 28, 2014. Novartis has an exclusive worldwide license option for the development and commercialization QPI-1002.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES